Trial Profile
A Pilot Study to Assess Tolerability of Subcutaneous Immunoglobulin Treatment (Hizentra) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2019
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Agammaglobulinaemia
- Focus Adverse reactions
- 07 May 2019 Status changed from recruiting to completed.
- 22 Jan 2018 New trial record